Holen Sie sich die Stockscreener-App
3.47
0.22%
-0.0075
Schlusskurs vom Vortag:
$3.4775
Offen:
$3.51
24-Stunden-Volumen:
3,092
Relative Volume:
0.30
Marktkapitalisierung:
$39.75M
Einnahmen:
$10.96M
Nettoeinkommen (Verlust:
$-7.02M
KGV:
-5.4219
EPS:
-0.64
Netto-Cashflow:
$-3.72M
1W Leistung:
-3.61%
1M Leistung:
-13.25%
6M Leistung:
-28.60%
1J Leistung:
-35.98%
1-Tages-Spanne:
$3.45
$3.60
1-Wochen-Bereich:
$3.45
$3.695
52-Wochen-Spanne:
$3.24
$6.75
Collplant Biotechnologies Ltd Stock (CLGN) Company Profile
Firmenname
Collplant Biotechnologies Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie CLGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLGN
Collplant Biotechnologies Ltd
|
3.47 | 39.75M | 10.96M | -7.02M | -3.72M | -0.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Collplant Biotechnologies Ltd Stock (CLGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-02-17 | Eingeleitet | Alliance Global Partners | Buy |
Collplant Biotechnologies Ltd Aktie (CLGN) Neueste Nachrichten
D. Boral Capital Reaffirms “Buy” Rating for CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World
CollPlant secures U.S. patent for dermal filler - Investing.com India
CollPlant secures U.S. patent for dermal filler By Investing.com - Investing.com Australia
CollPlant Biotechnologies Provides a Corporate Update - PR Newswire
Tissue Engineering Market: Key Player Profiles, Industry US$ - openPR
CollPlant Biotechnologies (NASDAQ:CLGN) Earns Buy Rating from D. Boral Capital - Defense World
Contrasting CollPlant Biotechnologies (NASDAQ:CLGN) and Pathfinder Cell Therapy (OTCMKTS:PFND) - Defense World
Collplant stock hits 52-week low at $3.24 amid market challenges By Investing.com - Investing.com South Africa
Collplant stock hits 52-week low at $3.24 amid market challenges - Investing.com India
CLGN (CollPlant Biotechnologies) 50-Day SMA : $4.31 (As of Dec. 01, 2024) - GuruFocus.com
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q3 2024 Earnings Call Transcript - MSN
CLGNCollPlant Biotechnologies Ltd Ordinary Shares Latest Stock News & Market Updates - StockTitan
CollPlant Biotechnologies Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
CollPlant Biotechnologies Ltd (CLGN) Q3 2024 Earnings Call Highlights: Navigating Revenue ... By GuruFocus - Investing.com Canada
CollPlant Biotechnologies Ltd (CLGN) Q3 2024 Earnings Call Highl - GuruFocus.com
CollPlant Biotechnologies Ltd (CLGN) Q3 2024 Earnings Call Highlights: Navigating Revenue ... - Yahoo Finance
CollPlant Biotechnologies’ Q3 2024 Financial Update - TipRanks
Q3 2024 Collplant Biotechnologies Ltd Earnings Call Transcript - GuruFocus.com
CollPlant Issues Letter to Shareholders - GuruFocus.com
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - PR Newswire
What To Expect From CollPlant Biotechnologies Ltd (CLGN) Q3 2024 Earnings - GuruFocus.com
Collplant stock hits 52-week low at $3.56 amid market challenges - Investing.com Canada
Collplant stock hits 52-week low at $3.56 amid market challenges By Investing.com - Investing.com South Africa
CollPlant Biotechnologies (CLGN) Set to Announce Earnings on Wednesday - Defense World
CollPlant (CLGN) to Report Q3 2024 Earnings on Nov 27: Conference Call Details | CLGN Stock News - StockTitan
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION – Company AnnouncementFT.com - Financial Times
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION - PR Newswire
Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Invest In Growth - Yahoo Finance
Collplant stock hits 52-week low at $3.61 amid market challenges - Investing.com Australia
500: Something went wrong - Investing.com India
Collplant stock hits 52-week low at $3.75 amid market challenges - Investing.com Australia
EF Hutton Initiates Coverage of CollPlant Biotechnologies (CLGN) with Buy Recommendation - MSN
Collplant stock hits 52-week low at $4.05 amid market challenges - Investing.com India
Collplant stock hits 52-week low at $4.05 amid market challenges By Investing.com - Investing.com South Africa
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Update - Defense World
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Up 5.3% in September - MarketBeat
Benjamin F. Edwards & Company Inc. Sells 10,690 Shares of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) - Defense World
CollPlant Shareholders Approve Key Proposals - TipRanks
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Sees Large Growth in Short Interest - MarketBeat
3D Bioprinting Market valued at USD 1.41 billion in 2024 | ExactitudeConsultancy - GlobeNewswire
CollPlant (CLGN), Stratasys Initiate Study for Breast Implants - MSN
CollPlant and Stratasys Launch Pre-clinical Trial for Regenerative 3D-Printed Breast Implants - 3DPrint.com
The Stratasys’ Origin® printer to be tested for CollPlant’s 3D-printed breast implants - 3d adept media
HC Wainwright Weighs in on CollPlant Biotechnologies Ltd.'s Q3 2024 Earnings (NASDAQ:CLGN) - MarketBeat
Head-To-Head Analysis: Envoy Medical (NASDAQ:COCH) and CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World
HC Wainwright Weighs in on CollPlant Biotechnologies Ltd.’s Q3 2024 Earnings (NASDAQ:CLGN) - Defense World
FY2027 EPS Estimates for CollPlant Biotechnologies Ltd. Reduced by HC Wainwright (NASDAQ:CLGN) - MarketBeat
HC Wainwright Research Analysts Cut Earnings Estimates for CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) - Defense World
Finanzdaten der Collplant Biotechnologies Ltd-Aktie (CLGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):